To investigate whether pharmacological blocking of the MEK1/2 pathway can inhibit the pathogenesis of S. aureus osteomyelitis, we treated mice with S. aureus osteomyelitis using PD0325901, an MEK1/2 inhibitor, in combination with gentamicin. Here, MAP2K1 is linked to osteomyelitis.